Human papillomavirus vaccine and systemic lupus erythematosus (Q45841999)

16 December 2017

title

Human papillomavirus vaccine and systemic lupus erythematosus (English)

1 reference

16 December 2017

systemic lupus erythematosus

1 reference

0 references

1 reference

16 December 2017

Yehuda Shoenfeld

series ordinal

object named as

Yehuda Shoenfeld

1 reference

16 December 2017

Nancy Agmon-Levin

1 reference

16 December 2017

Andrea Doria

1 reference

16 December 2017

Shaye Kivity

1 reference

16 December 2017

Ramit Maoz-Segal

1 reference

16 December 2017

Alessandra Soriano

series ordinal

object named as

Alessandra Soriano

1 reference

16 December 2017

author name string

Mariele Gatto

series ordinal

1 reference

16 December 2017

publication date

28 April 2013

1 reference

16 December 2017

published in

Clinical Rheumatology

1 reference

16 December 2017

volume

1 reference

16 December 2017

issue

1 reference

16 December 2017

page(s)

1301-1307

1 reference

16 December 2017

Human papillomavirus infection and the development of cervical cancer and related genital neoplasias

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

HPV infection and cervical disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

The new H1N1 and HPV vaccines and old fears

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Systemic lupus erythematosus following HPV immunization or infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Systemic lupus erythematosus one disease or many?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Emerging and critical issues in the pathogenesis of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Vaccines and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Infections as triggers and complications of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Ten cases of systemic lupus erythematosus related to hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Immune-mediated myelitis following hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Adjuvants and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Are women with lupus at higher risk of HPV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Lupus: improving long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

SLE diagnosis and treatment: when early is early

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Vaccination and autoimmune rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Demyelinating disease and polyvalent human papilloma virus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

CNS demyelination and quadrivalent HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Immunization of patients with autoimmune inflammatory rheumatic diseases (the EULAR recommendations).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2266-7

Long-term prognosis and causes of death in systemic lupus erythematosus

21 January 2018

1 reference

12 December 2020

No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?

1 reference

12 December 2020

Missense polymorphisms within IL-10R1 exons are not associated with systemic lupus erythematosus in Chinese

1 reference

12 December 2020

Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

1 reference

12 December 2020

Quantifying the efficacy of influenza vaccines

1 reference

12 December 2020

Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study

1 reference

12 December 2020

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

1 reference

12 December 2020

Vaccines and autoimmune diseases of the adult.

1 reference

12 December 2020

10.1007/S10067-013-2266-7

Identifiers

DOI

1 reference

16 December 2017

1 reference

16 December 2017